Sulindac metabolism: the importance of an intact colon
- PMID: 4042521
- DOI: 10.1038/clpt.1985.192
Sulindac metabolism: the importance of an intact colon
Abstract
The pharmacokinetics of sulindac have been studied after a single 200 mg oral dose in six normal subjects and five patients with surgical ileostomies. The plasma concentration-time curves for sulindac were similar in both groups up to 12 hours after dosing, indicating similar absorption of the drug. Higher plasma concentrations of sulindac were found in normal subjects after 12 hours, but this late phase accounted for only 12% of the total AUC in the subjects. The sulfone metabolite showed a similar pattern, with no statistically significant difference in the total AUC, but in patients with ileostomy there was a halving of the AUC after 12 hours. Plasma concentrations of the active sulfide metabolite were similar in both groups up to 12 hours, but negligible concentrations were detected in the plasma of patients with ileostomy after 12 hours. Thus the AUC after 12 hours, which represented 55% of the total AUC in normal subjects, was reduced to only 7% in patients with ileostomy. The rate of reduction of sulindac in vitro by ileostomy effluent was only one hundredth that by normal feces. Our results suggest that the gut microflora are an important site of reduction of sulindac in man. Comparison of AUC values suggests that about half the total sulfide is formed by the gut bacteria, probably from sulindac excreted in the bile.
Similar articles
-
Biotransformation of sulindac in end-stage renal disease.Clin Pharmacol Ther. 1987 Jul;42(1):82-8. doi: 10.1038/clpt.1987.112. Clin Pharmacol Ther. 1987. PMID: 3595070
-
Effects of age and disease on the pharmacokinetics and pharmacodynamics of sulindac.Clin Pharmacol Ther. 1985 Aug;38(2):228-34. doi: 10.1038/clpt.1985.163. Clin Pharmacol Ther. 1985. PMID: 4017423
-
Pharmacokinetics of graded oral doses of sulindac in man.Arzneimittelforschung. 1984;34(2):226-9. Arzneimittelforschung. 1984. PMID: 6539116
-
Sulindac: therapeutic implications of the prodrug/pharmacophore equilibrium.Drug Metab Rev. 1981;12(2):325-37. doi: 10.3109/03602538108994035. Drug Metab Rev. 1981. PMID: 7040018 Review.
-
Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.Clin Pharmacokinet. 2007;46(1):13-58. doi: 10.2165/00003088-200746010-00002. Clin Pharmacokinet. 2007. PMID: 17201457 Review.
Cited by
-
Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study.J Thorac Oncol. 2008 Sep;3(9):1018-25. doi: 10.1097/JTO.0b013e3181834fa1. J Thorac Oncol. 2008. PMID: 18758305 Free PMC article. Clinical Trial.
-
COX-Independent Mechanisms of Cancer Chemoprevention by Anti-Inflammatory Drugs.Front Oncol. 2013 Jul 11;3:181. doi: 10.3389/fonc.2013.00181. eCollection 2013. Front Oncol. 2013. PMID: 23875171 Free PMC article.
-
Sulindac for stroke treatment: neuroprotective mechanism and therapy.Neural Regen Res. 2014 Dec 1;9(23):2023-5. doi: 10.4103/1673-5374.147919. Neural Regen Res. 2014. PMID: 25657710 Free PMC article. No abstract available.
-
Biotransformation of BOF-4272, a sulfoxide-containing drug, in the cynomolgus monkey.Eur J Drug Metab Pharmacokinet. 1999 Jul-Sep;24(3):279-86. doi: 10.1007/BF03190032. Eur J Drug Metab Pharmacokinet. 1999. PMID: 10716068
-
Nonsteroidal anti-inflammatory drug sulindac sulfide suppresses structural protein Nesprin-2 expression in colorectal cancer cells.Biochim Biophys Acta. 2014 Jan;1840(1):322-31. doi: 10.1016/j.bbagen.2013.09.032. Epub 2013 Sep 27. Biochim Biophys Acta. 2014. PMID: 24080406 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources